How leading developers are rethinking strategy, execution, and risk in engineered immunotherapy programs for solid tumors.
Engineered immune therapies represent the next generation of immunotherapies, enabling more precise targeting and novel mechanisms designed to overcome the biological barriers that have limited success in solid tumors. These approaches have already transformed outcomes in hematologic malignancies yet translating that success to solid tumors has proven far more complex. Scientific innovation alone is not enough. Early development decisions around trial design, safety strategy, and regulatory engagement often determine whether promising programs advance or stall.
In this webinar, leaders developing these next-generation immunotherapies for solid tumors share practical insights drawn from real-world experience. The discussion will focus on how biopharma teams are designing deliberately scoped early phase trials to inform confident development decisions, managing safety without slowing momentum, planning for combination strategies, and aligning with regulators to reduce risk and accelerate development timelines.
What You’ll Take Away
- A clearer framework for designing early-phase trials that inform go/no-go decisions, not just generate data
- Practical approaches to managing safety proactively without slowing development momentum
- Insights into when and how to plan for combination strategies in solid tumor programs
- Lessons on early regulatory engagement that reduces downstream risk and surprises
- Real-world examples of development decisions that have accelerated or derailed engineered immunotherapy programs
Who Should Attend
Biopharma leaders in early clinical development, translational medicine, regulatory strategy, and portfolio planning working on engineered or cell-based immunotherapies for solid tumors.
Offered Free by: Allucent
See All Resources from: Allucent
